

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

UNITED STATES PATENT APPLICATION

OF

DAVID F. CARMICHAEL,

DAVID C. ANDERSON,

GEORGE P. STRICKLIN,

AND

HOWARD G. WELGUS

FOR

METALLOPROTEINASE INHIBITOR SEQUENCE  
RECOMBINANT VECTOR SYSTEM FOR USING SAME AND  
RECOMBINANT-DNA METHOD FOR THE MANUFACTURE OF SAME

LAW OFFICES  
FINNEGAN, HENDERSON  
FARABOW, GARRETT  
& DUNNER  
1775 K STREET, N.W.  
WASHINGTON, D.C. 20006  
(202) 293-6650

BACKGROUND OF THE INVENTION

This is a continuation -in-part application of U.S. Patent Application Serial No. 699,181, filed February 5, 1985.

Endogenous proteolytic enzymes serve to degrade invading organisms, antigen-antibody complexes and certain tissue proteins which are no longer necessary or useful to the organism. In a normally functioning organism, proteolytic enzymes are produced in a limited quantity and are regulated in part through specific inhibitors.

Metalloproteinases are enzymes present in the body which are often involved in the degradation of connective tissue. While some connective tissue degradation is necessary for normal functioning of an organism, an excess of connective tissue degradation occurs in several disease states and is believed to be attributable, at least in part, to excess metalloproteinase. It is believed that metalloproteinases are at least implicated in periodontal disease, corneal and skin ulcers, rheumatoid arthritis and the spread of cancerous solid tumors.

These diseases generally occur in areas of the body which contain a high proportion of collagen, a particular form of connective tissue. An examination of patients with these diseases of connective tissue has revealed an excessive breakdown of the various components of connective tissues, including collagen proteoglycans and elastin. Therefore, it has been deduced that

an excessive concentration of a particular metalloproteinase, for example collagenase, proteoglycanase, gelatinase, and certain elastases, may cause or exacerbate the connective tissue destruction associated with the aforementioned diseases.

In the normal state, the body possesses metalloproteinase inhibitors which bind to metalloproteinases to effectively prevent these enzymes from acting on their connective tissue substrates. Specifically, in a healthy organism, metalloproteinase inhibitors are present in concentrations sufficient to interact with metalloproteinases to an extent which allows sufficient quantities of metalloproteinase to remain active while binding the excess metalloproteinase so that the connective tissue damage seen in the various diseases does not occur.

It is postulated that one immediate cause of the connective tissue destruction present in the foregoing disease states is an imbalance in the relative metalloproteinase/metalloproteinase inhibitor concentrations. In these situations, either due to an excessive amount of active metalloproteinase or a deficiency in the amount of active metalloproteinase inhibitor, the excess metalloproteinase is believed to cause the connective tissue degradation responsible for causing or exacerbating the disease. It is postulated that, by treating persons with connective tissue diseases with metalloproteinase inhibitors, the degradative action of the excess metalloproteinase may be curtailed or

halted. Therefore, particular metalloproteinase inhibitors of specific interest to the present inventors are collagenase inhibitors because it is believed that these inhibitors would be pharmaceutically useful in the treatment or prevention of connective tissue diseases.

The existence of metalloproteinase and metalloproteinase inhibitors has been discussed in the scientific literature. For example, Sellers et al., Biochemical And Biophysical Research Communications 87:581-587 (1979), discusses isolation of rabbit bone collagenase inhibitor. Collagenase inhibitor isolated from human skin fibroblasts is discussed in Stricklin and Welgus, J.B.C. 258:12252-12258 (1983) and Welgus and Stricklin, J.B.C. 258:12259-12264 (1983). The presence of collagenase inhibitors in naturally-occurring body fluids is further discussed in Murphy et al., Biochem. J. 195:167-170 (1981) and Cawston et al., Arthritis and Rheumatism, 27:285 (1984). In addition, metalloproteinase inhibitors are discussed by Reynolds et al. in Cellular Interactions, Dingle and Gordon, eds., (1981). Although these articles characterize particular, isolated metalloproteinase inhibitors and discuss, to some extent, the role or potential role of metalloproteinases in connective tissue disease treatment and speculate on the ability of metalloproteinase inhibitors to counteract this destruction, none of these researchers had previously been able to isolate a portable DNA

*Juls  
P1*

sequence capable of directing intracellular production of metalloproteinase inhibitors or to create a recombinant-DNA method for the production of these inhibitors.

Surprisingly, the present inventors have discovered a portable DNA sequence capable of directing the recombinant-DNA synthesis of metalloproteinase inhibitors. These metalloproteinase inhibitors are biologically equivalent to those isolated from human skin fibroblast cultures. The metalloproteinase inhibitors of the present invention, prepared by the recombinant-DNA methods set forth herein, will enable increased research into prevention and treatment of metalloproteinase-induced connective tissue diseases. In addition, the metalloproteinase inhibitors of the present invention are useful in neutralizing metalloproteinases, including the excess metalloproteinase associated with disease states. Therefore, it is believed that a cure for these diseases will be developed which will embody, as an active ingredient, the metalloproteinase inhibitors of the present invention. Furthermore, the metalloproteinase inhibitors of the present invention are capable of interacting with their metalloproteinase targets in a manner which allows the development of diagnostic tests for degradative connective tissue diseases using the newly discovered inhibitors.

The recombinant metalloproteinase inhibitors discussed herein interact stoichiometrically (i.e., in a 1:1 ratio) with their

metalloproteinase targets. In addition, these metalloproteinase inhibitors are heat resistant, acid stable, glycosylated, and exhibit a high isoelectric point.

#### SUMMARY OF THE INVENTION

The present invention relates to metalloproteinase inhibitors and a recombinant-DNA method of producing the same and to portable DNA sequences capable of directing intracellular production of the metalloproteinase inhibitors. Particularly, the present invention relates to a collagenase inhibitor, a recombinant-DNA method for producing the same and to portable DNA sequences for use in the recombinant method. The present invention also relates to a series of vectors containing these portable DNA sequences.

One object of the present invention is to provide a metalloproteinase inhibitor, which can be produced in sufficient quantities and purities to provide economical pharmaceutical compositions which possess metalloproteinase inhibitor activity.

An additional object of the present invention is to provide a recombinant-DNA method for the production of these metalloproteinase inhibitors. The recombinant metalloproteinase inhibitors produced by this method are biologically equivalent to the metalloproteinase inhibitor isolable from human skin fibroblast cultures.

To facilitate the recombinant-DNA synthesis of these metalloproteinases inhibitors, it is a further object of the present invention to provide portable DNA sequences capable of directing intracellular production of metalloproteinase inhibitors. It is also an object of the present invention to provide cloning vectors containing these portable sequences. These vectors are capable of being used in recombinant systems to produce pharmaceutically useful quantities of metalloproteinase inhibitors.

Additional objects and advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description or may be learned from practice of the invention. The objects and advantages may be realized and attained by means of the instrumentalities and combinations particularly pointed out in the appended claims.

To achieve the objects and in accordance with the purposes of the present invention, metalloproteinase inhibitors are set forth, which are capable of stoichiometric reaction with metalloproteinases. These metalloproteinase inhibitors are remarkably heat resistant, acid stable, glycosylated, and exhibit a high isoelectric point. Furthermore, these metalloproteinase inhibitors are biologically equivalent to those inhibitors isolated from human skin fibroblast cultures.

To further achieve the objects and in accordance with the purposes of the present invention, as embodied and broadly

described herein, portable DNA sequences coding for metalloproteinase inhibitors are provided. These sequences comprise nucleotide sequences capable of directing intracellular production of metalloproteinase inhibitors. The portable sequences may be either synthetic sequences or restriction fragments ("natural" DNA sequences). In a preferred embodiment, a portable DNA sequence is isolated from a human fibroblast cDNA library and is capable of directing intracellular production of a collagenase inhibitor which is biologically equivalent to that inhibitor which is isolable from a human skin fibroblast culture.

*Sub B2* The coding strand of a first preferred DNA sequence which has been discovered has the following nucleotide sequence:

10	20	30	40	50	60
GTTGTTGCTG TGGCTGATAG CCCCAGCAGG GCCTGCACCT GTGTCCCACC CCACCCACAG					
70	80	90	100	110	120
ACGGCCTTCT GCAATTCCGA CCTCGTCATC AGGGCCAAGT TCGTGGGGAC ACCAGAAGTC					
130	140	150	160	170	180
AACCAGACCA CCTTATAACCA GCGTTATGAG ATCAAGATGA CCAAGATGTA TAAAGGGTTC					
190	200	210	220	230	240
CAAGCCTTAG GGGATGCCGC TGACATCCGG TTCGTCTACA CCCCCGCCAT GGAGAGTGTC					
250	260	270	280	290	300
TGCGGATACT TCCACAGGTC CCACAACCGC AGCGAGGAGT TTCTCATTGC TGGAAAATG					
310	320	330	340	350	360
CAGGATGGAC TCTTGCACAT CACTACCTGC AGTTTCGTGG CTCCCTGGAA CAGCCTGAGC					
370	380	390	400	410	420
TTAGCTCAGC GCCGGGGCTT CACCAAGACC TACACTGTTG GCTGTGAGGA ATGCACAGTG					
430	440	450	460	470	480
TTTCCCTGTT TATCCATCCC CTGCAAATG CAGAGTGGCA CTCATTGCTT GTGGACGGAC					

54

490	500	510	520	530	
CAGCTCCTCC AAGGCTCTGA AAAGGGCTTC CAGTCCCGTC ACCTTGCCCTG CCTGCCTCG					
550	560	570	580	590	60
GAGCCAGGGC TGTGCACCTG GCAGTCCCTG CGGTCCCAGA TAGCCTGAAT CCTGCCCGG					
610	620	630	640	650	66
GTGGAAGCTG AAGCCTGCAC AGTGTCCACC CTGTTCCCAC TCCCATCTTT CTTCCGGAC					
670	680	690	700		
ATGAAATAAA GAGTTACCAAC CCAGCAAAAA AAAAAAGGAA TTC					

The nucleotides represented by the foregoing abbreviations are set forth in the Detailed Description of the Preferred Embodiments.

A second preferred DNA sequence has been discovered which has an additional nucleotide sequence 5' to the initiator sequence. This sequence, which contains as the eighty-second through four-hundred-thirty-second nucleotides nucleotides 1 through 351 of the first preferred sequence set forth above, has the following nucleotide sequence:

6

10	20	30	40	50	
GGCCATCGCC GCAGATCCAG CGCCCAGAGA GACACCAGAG AACCCACCAT GGCCCCCT					
70	80	90	100	110	1
GACCCCTGGC TTCTGCATCC TGTGTTGCT GTGGCTGATA GCCCCAGCAG GGCCTGCA					
130	140	150	160	170	1
TGTGTCCCAC CCCACCCACA GACGGCCTTC TGCAATTCCG ACCTCGTCAT CAGGGCCA					
190	200	210	220	230	2
TTCGTGGGGA CACCAGAAGT CAACCAGACC ACCTTATACC AGCGTTATGA GATCAAGA					
250	260	270	280	290	3
ACCAAGATGT ATAAAGGGTT CCAAGCCTTA GGGGATGCCG CTGACATCCG GTTCGTCT					
310	320	330	340	350	3
ACCCCCGCCA TGGAGAGTGT CTGCGGATAAC TTCCACAGGT CCCACAACCG CAGCGAGG					

370 380 390 400 410 420  
TTTCTCATTG CTGGAAA ACT GCAGGATGGA CTCTTCACA TCACTACCTG CAGTTTCGT

430  
GCTCCCTGGAA AC

*Sub B4*  
A third preferred DNA sequence which incorporates the 5' region of the second preferred sequence and the 3' sequence of the first preferred sequence, has the following nucleotide sequence:

10 20 30 40 50 60  
GGCCATCGCC GCAGATCCAG CGCCCAGAGA GACACCAGAG AACCCACCAT GGCCCCCTT

70 80 90 100 110 120  
GACCCCTGGC TTCTGCATCC TGTTGTTGCT GTGGCTGATA GCCCCAGCAG GGCCTGCAC

130 140 150 160 170 180  
TGTGTCCCAC CCCACCCACA GACGGCCTTC TGCAATTCCG ACCTCGTCAT CAGGGCCAA

190 200 210 220 230 240  
TTCGTGGGGA CACCAAGAAGT CAACCAGACC ACCTTATACC AGCGTTATGA GATCAAGAT

250 260 270 280 290 300  
ACCAAGATGT ATAAAGGGTT CCAAGCCTTA GGGGATGCCG CTGACATCCG GTTCGTCTA

310 320 330 340 350 360  
ACCCCCGCCA TGGAGAGTGT CTGCGGATAC TTCCACAGGT CCCACAACCG CAGCGAGGA

370 380 390 400 410 420  
TTTCTCATTG CTGGAAA ACT GCAGGATGGA CTCTTCACA TCACTACCTG CAGTTTCGT

430 440 450 460 470 480  
GCTCCCTGGA ACAGCCTGAG CTTAGCTCAG CGCCGGGGCT TCACCAAGAC CTACACTGT

490 500 510 520 530 540  
GGCTGTGAGG AATGCACAGT GTTCCCTGT TTATCCATCC CCTGCAAACCT GCAGAGTGG

550 560 570 580 590 600  
ACTCATTGCT TGTGGACGGA CCAGCTCCTC CAAGGCTCTG AAAAGGGCTT CCAGTCCCC

610 620 630 640 650 660  
CACCTTGCT GCCTGCCTCG GGAGCCAGGG CTGTGCACCT GGCAGTCCCT GCGGTCCCC

670 680 690 700 710 720  
ATAGCCTGAA TCCTGCCCGG AGTGGAAAGCT GAAGCCTGCA CAGTGTCCAC CCTGTTCCC

730            740            750            760            770            780  
CTCCCCATCTT TCTTCCGGAC AATGAAATAA AGAGTTACCA CCCAGCAAAA AAAAAAAAGGA

To facilitate identification and isolation of natural DNA sequences for use in the present invention, the inventors have developed a human skin fibroblast cDNA library. This library contains the genetic information capable of directing a cell to synthesize the metalloproteinase inhibitors of the present invention. Other natural DNA sequences which may be used in the recombinant DNA methods set forth herein may be isolated from human genomic libraries.

Additionally, portable DNA sequences useful in the processes of the present invention may be synthetically created. These synthetic DNA sequences may be prepared by polynucleotide synthesis and sequencing techniques known to those of ordinary skill in the art.

Additionally, to achieve the objects and in accordance with the purposes of the present invention, a recombinant-DNA method is disclosed which results in microbial manufacture of the instant metalloproteinase inhibitors using the portable DNA sequences referred to above. This recombinant DNA method comprises:

- (a) preparation of a portable DNA sequence capable of directing a host microorganism to produce a protein having metalloproteinase inhibitor activity, preferably collagenase inhibitor activity;

- (b) cloning the portable DNA sequence into a vector capable of being transferred into and replicating in a host microorganism, such vector containing operational elements for the portable DNA sequence;
- (c) transferring the vector containing the portable DNA sequence and operational elements into a host microorganism capable of expressing the metalloproteinase inhibitor protein;
- (d) culturing the host microorganism under conditions appropriate for amplification of the vector and expression of the inhibitor; and
- (e) in either order:
  - (i) harvesting the inhibitor; and
  - (ii) causing the inhibitor to assume an active, tertiary structure whereby it possesses metalloproteinase inhibitor activity.

To further accomplish the objects and in further accord with the purposes of the present invention, a series of cloning vectors are provided comprising at least one of the portable DNA sequences discussed above. In particular, plasmid pUC9-F5/237P10 is disclosed.

It is understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed.

The accompanying drawing, which is incorporated in and constitutes a part of this specification, illustrates one embodiment of the invention and, together with the description, serves to explain the principles of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a partial restriction map of the plasmid pUC9-F5/237P10.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Reference will now be made in detail to the presently preferred embodiments of the invention, which, together with the drawing and the following examples, serve to explain the principles of the invention.

As noted above, the present invention relates in part to portable DNA sequences capable of directing intracellular production of metalloproteinase inhibitors in a variety of host microorganisms. "Portable DNA sequence" in this context is intended to refer either to a synthetically-produced nucleotide sequence or to a restriction fragment of a naturally occurring DNA sequence. For purposes of this specification, "metalloproteinase inhibitor" is intended to mean the primary structure of the protein as defined by the codons present in the deoxyribonucleic acid sequence which directs intracellular production of the amino acid sequence, and which may or may not include post-translational modifications. It is contemplated that such

post-translational modifications include, for example, glycosylation. It is further intended that the term "metalloproteinase inhibitor" refer to either the form of the protein as would be excreted from a microorganism or the methionyl-metallocproteinase inhibitor as it may be present in microorganisms from which it was not excreted.

In a preferred embodiment, the portable DNA sequences are capable of directing intracellular production of collagenase inhibitors. In a particularly preferred embodiment, the portable DNA sequences are capable of directing intracellular production of a collagenase inhibitor biologically equivalent to that previously isolated from human skin fibroblast cultures. By "biologically equivalent", as used herein in the specification and claims, it is meant that an inhibitor, produced using a portable DNA sequence of the present invention, is capable of preventing collagenase-induced tissue damage of the same type, but not necessarily to the same degree, as a native human collagenase inhibitor, specifically that native human collagenase inhibitor isolable from human skin fibroblast cell cultures.

A first preferred portable DNA sequence of the present invention has a nucleotide sequence as follows:

10            20            30            40            50            60  
 GTTGTGCTG TGGCTGATAG CCCCAGCAGG GCCTGCACCT GTGTCCCACC CCACCCACAG

70            80            90            100          110          120  
 ACGGCCTTCT GCAATTCCGA CCTCGTCATC AGGGCCAAGT TCGTGGGGAC ACCAGAAGTC

130          140          150          160          170          180  
 AACCAAGACCA CCTTATAACCA GCGTTATGAG ATCAAGATGA CCAAGATGTA TAAAGGGTTC

190          200          210          220          230          240  
 CAAGCCTTAG GGGATGCCGC TGACATCCGG TTCGTCTACA CCCCCGCCAT GGAGAGTGTC

250          260          270          280          290          300  
 TGCGGATACT TCCACAGGTC CCACAAACCGC AGCGAGGGAGT TTCTCATTGC TGGAAAATG

310          320          330          340          350          360  
 CAGGATGGAC TCTTGCACAT CACTACCTGC AGTTTCGTGG CTCCCTGGAA CAGCCTGAGC

370          380          390          400          410          420  
 TTAGCTCAGC GCCGGGGCTT CACCAAGACC TACACTGTTG GCTGTGAGGA ATGCACAGTG

430          440          450          460          470          480  
 TTTCCCTGTT TATCCATCCC CTGCAAACGT CAGAGTGGCA CTCATTGCTT GTGGACGGAC

490          500          510          520          530          540  
 CAGCTCCTCC AAGGCTCTGA AAAGGGCTTC CAGTCCCGTC ACCTTGCCTG CCTGCCTCGG

550          560          570          580          590          600  
 GAGCCAGGGC TGTGCACCTG GCAGTCCCTG CGGTCCCAGA TAGCCTGAAT CCTGCCCGGA

610          620          630          640          650          660  
 GTGGAAGCTG AAGCCTGCAC AGTGTCCACC CTGTTCCCAC TCCCATCTTT CTTCCGGAC

670          680          690          700  
 ATGAAATAAA GAGTTACAC CCAGCAAAAA AAAAAAGGAA TTC

wherein the following nucleotides are represented by the abbreviations indicated below.

LAW OFFICES  
 FINNEGAN, HENDERSON  
 FARABOW, GARRETT  
 & DUNNER  
 1775 K STREET, N.W.  
 WASHINGTON, D.C. 20006  
 (202) 293-6850

NucleotidesAbbreviation

Deoxyadenylic acid

A

Deoxyguanylic acid

G

Deoxycytidylic acid

C

Thymidylic acid

T

*Inv B6*  
*Sub B7* A second preferred portable DNA sequence of the present invention has the following nucleotide sequence:

10	20	30	40	50	60
GGCCATCGCC	GCAGATCCAG	CGCCCAGAGA	GACACCAGAG	AACCCACCAT	GGCCCCCTTT
70	80	90	100	110	120
GACCCTGGC	TTCTGCTATCC	TGTTGTTGCT	GTGGCTGATA	GCCCCAGCAG	GGCCTGCACC
130	140	150	160	170	180
TGTGTCTCAC	CCCACCCACA	GACGGCCTTC	TGCAATTCCG	ACCTCGTCAT	CAGGGCCAAG
190	200	210	220	230	240
TTCGTGGGGA	CACCAGAACT	CAACCAGACC	ACCTTATAACC	AGCGTTATGA	GATCAAGATG
250	260	270	280	290	300
ACCAAGATGT	ATAAAGGGTT	CCAAGCCTTA	GGGGATGCCG	CTGACATCCG	TTTCGTCTAC
310	320	330	340	350	360
ACCCCCGCCA	TGGAGAGTGT	CTGCGGATAC	TTCCACAGGT	CCCACAAACCG	CAGCGAGGAG
370	380	390	400	410	420
TTTCTCATGG	CTGGAAAACT	GCAGGATGGA	CTCTTGCACA	TCACTACCTG	CAGTTTCGTC
430					
GCTCCCTGGAA AC					

*Sub B8*

In this second preferred sequence, an open reading frame exists from nucleotides 1 through 432. The first methionine of this reading frame is encoded by nucleotides by 49 through 51 and is the site of translation initiation. It should be noted that the amino acid sequence prescribed nucleotides 49 through 114 is not

*Sub B9*

found in the mature metalloprotein. It is believed that this sequence is the leader peptide of the human protein.

A third preferred portable DNA sequence has the nucleotide sequence:

10            20            30            40            50            60  
GGCCATCGCC GCAGATCCAG CGCCCAGAGA GACACCAGAG AACCCACCAT GGCCCCCTTT

70            80            90            100          110          120  
GACCCCTGGC TTCTGCATCC TGTTGTTGCT GTGGCTGATA GCCCCAGCAG GGCCTGCACC

130          140          150          160          170          180  
TGTGTCCCAC CCCACCCACA GACGGCCTTC TGCAATTCCG ACCTCGTCAT CAGGGCCAAG

190          200          210          220          230          240  
TTCGTGGGA CACCAGAACT CAACCAGACC ACCTTATACC AGCGTTATGA GATCAAGATG

250          260          270          280          290          300  
ACCAAGATGT ATAAAGGGTT CCAAGCCTTA GGGGATGCCG CTGACATCCG GTTCGTCTAC

310          320          330          340          350          360  
ACCCCCGCCA TGGAGAGTGT CTGGGATAC TTCCACAGGT CCCACAACCG CAGCGAGGAG

370          380          390          400          410          420  
TTTCTCATTG CTGGAAAATC GCAGGATGGA CTCTTGACACA TCACTACCTG CAGTTTCGTG

430          440          450          460          470          480  
GCTCCCTGGA ACAGCCTGAG CTTAGCTCAG CGCCGGGGCT TCACCAAGAC CTACACTGTT

490          500          510          520          530          540  
GGCTGTGAGG AATGCACAGT GTTTCCCTGT TTATCCATCC CCTGCAAACCT GCAGAGTGGC

550          560          570          580          590          600  
ACTCATTGCT TGTGGACGGA CCAGCTCCTC CAAGGCTCTG AAAAGGGCTT CCAGTCCCGT

610          620          630          640          650          660  
CACCTTGCCT GCCTGCCTCG GGAGCCAGGG CTGTGCACCT GGCAGTCCCT GCGGTCCCAG

670          680          690          700          710          720  
ATAGCCTGAA TCCTGCCCGG AGTGGAAAGCT GAAGCCTGCA CAGTGTCCAC CCTGTTCCCA

730          740          750          760          770          780  
CTCCCATCTT TCTTCCGGAC AATGAAATAA AGAGTTACCA CCCAGAAAAA AAAAAAAAGGA

This third sequence contains the 5' nontranslated region of the second preferred sequence and the 3' region of the first preferred sequence. It is envisioned that this third preferred sequence is capable of directing intracellular production of a metalloproteinase analogous to a mature human collagenase inhibitor in a microbial or mammalian expression system.

It must be borne in mind in the practice of the present invention that the alteration of some amino acids in a protein sequence may not affect the fundamental properties of the protein. Therefore, it is also contemplated that other portable DNA sequences, both those capable of directing intracellular production of identical amino acid sequences and those capable of directing intracellular production of analogous amino acid sequences which also possess metalloproteinase inhibitor activity, are included within the ambit of the present invention.

It is contemplated that some of these analogous amino acid sequences will be substantially homologous to native human metalloproteinase inhibitors while other amino acid sequences, capable of functioning as metalloproteinase inhibitors, will not exhibit substantial homology to native inhibitors. By "substantial homology", as used herein, is meant a degree of homology to a native metalloproteinase inhibitor in excess of 50%, preferably in excess of 60%, preferably in excess of 80%. The percentage homology as discussed herein is calculated as the percentage of

amino acid residues found in the smaller of the two sequences that align with identical amino acid residues in the sequence being compared when four gaps in a length of 100 amino acids may be introduced to assist in that alignment as set forth by Dayhoff, M.O. in Atlas of Protein Sequence and Structure Vol. 5, p. 124 (1972), National Biochemical Research Foundation, Washington, D.C., specifically incorporated herein by reference.

As noted above, the portable DNA sequences of the present invention may be synthetically created. It is believed that the means for synthetic creation of these polynucleotide sequences are generally known to one of ordinary skill in the art, particularly in light of the teachings contained herein. As an example of the current state of the art relating to polynucleotide synthesis, one is directed to Matteucci, M.D. and Caruthers, M.H., in J. Am. Chem. Soc. 103: 3185 (1981) and Beauchage, S.L. and Caruthers, M.H. in Tetrahedron Lett. 22: 1859 (1981), specifically incorporated herein by reference.

Additionally, the portable DNA sequence may be a fragment of a natural sequence, i.e., a fragment of a polynucleotide which occurred in nature and which has been isolated and purified for the first time by the present inventors. In one embodiment, the portable DNA sequence is a restriction fragment isolated from a cDNA library. In this preferred embodiment, the cDNA library is created from human skin fibroblasts.

In an alternative embodiment, the portable DNA sequence is isolated from a human genomic library. An example of such a library useful in this embodiment is set forth in Lawn et al. Cell 15: 1157-1174 (1978), specifically incorporated herein by reference.

As also noted above, the present invention relates to a series of vectors, each containing at least one of the portable DNA sequences described herein. It is contemplated that additional copies of the portable DNA sequence may be included in a single vector to increase a host microorganism's ability to produce large quantities of the desired metalloproteinase inhibitor.

In addition, the cloning vectors within the scope of the present invention may contain supplemental nucleotide sequences preceding or subsequent to the portable DNA sequence. These supplemental sequences are those that will not interfere with transcription of the portable DNA sequence and will, in some instances as set forth more fully hereinbelow, enhance transcription, translation, or the ability of the primary amino acid structure of the resultant metalloproteinase inhibitor to assume an active, tertiary form.

A preferred vector of the present invention is set forth in Figure 1. This vector, pUC9-F5/237P10, contains the preferred nucleotide sequence set forth above. Vector pUC9-F5/237P10 is present in the C600/pUC9-F5/237P10 cells on deposit in the

American Type Culture Collection in Rockville, Maryland under Accession No. 53003.

A preferred nucleotide sequence encoding the metalloproteinase inhibitor is identified in Figure 1 as region A. Plasmid pUC9-F5/237P10 also contains supplemental nucleotide sequences preceding and subsequent to the preferred portable DNA sequence in region A. These supplemental sequences are identified as regions B and C, respectively.

In alternate preferred embodiments, either one or both of the preceding or subsequent supplemental sequences may be removed from the vector of Fig. 1 by treatment of the vector with restriction endonucleases appropriate for removal of the supplemental sequences. The supplemental sequence subsequent to the portable DNA sequence, identified in Fig. 1 as region C, may be removed by treatment of the vector with a suitable restriction endonuclease, preferably HqiAI followed by reconstruction of the 3' end of region A using synthetic oligonucleotides and ligation of the vector with T-4 DNA ligase. Deletion of the supplemental sequence preceding the portable DNA sequence, identified as region B in Fig. 1, would be specifically accomplished by the method set forth in Example 2.

In preferred embodiments, cloning vectors containing and capable of expressing the portable DNA sequence of the present invention contain various operational elements. These

"operational elements," as discussed herein, include at least one promoter, at least one Shine-Dalgarno sequence, at least one terminator codon. Preferably, these "operational elements" also include at least one operator, at least one leader sequence, and for proteins to be exported from intracellular space, at least one regulator and any other DNA sequences necessary or preferred for appropriate transcription and subsequent translation of the vector DNA.

Additional embodiments of the present invention are envisioned as employing other known or currently undiscovered vectors which would contain one or more of the portable DNA sequences described herein. In particular, it is preferred that these vectors have some or all of the following characteristics: (1) possess a minimal number of host-organism sequences; (2) be stable in the desired host; (3) be capable of being present in a high copy number in the desired host; (4) possess a regulatable promoter; (5) have at least one DNA sequence coding for a selectable trait present on a portion of the plasmid separate from that where the portable DNA sequence will be inserted; and (6) be integrated into the vector.

The following, noninclusive, list of cloning vectors is believed to set forth vectors which can easily be altered to meet the above-criteria and are therefore preferred for use in the present invention. Such alterations are easily performed by

those of ordinary skill in the art in light of the available literature and the teachings herein.

TABLE I

HOST	VECTORS	Comments
<u>E. coli</u>	pUC8 pUC9 pBR322 pGW7 placI <sup>q</sup> pDP8	Many selectable replicons have been characterized. Maniatis, T. et al. (1982), <u>Molecular Cloning: A Laboratory Manual</u> , Cold Spring Harbor Laboratory.
<u>BACILLUS</u> <u>B. subtilis</u> <u>B. amyloliquefaciens</u> <u>B. stearothermophilus</u>	pUB110 pSA0501 pSA2100 pBD6 pBD8 pT127	<u>Genetics and Biotechnology of Bacilli</u> , Ganesan and Hoch, eds., 1984, Academic Press.
<u>PSEUDOMONAS</u> <u>P. aeruginosa</u> <u>P. putida</u>	RSF1010 Rms149 pKT209 RK2 pSa727	Some vectors useful in broad host range of gram-negative bacteria including Xanthomonas and Agrobacteri
<u>CLOSTRIDIUM</u> <u>C. perfringens</u>	pJU12 pJU7 pJU10 pJU16 pJU13	Shuttle plasmids for <u>E. coli</u> and <u>C. perfringens</u> construction ref. Squires, C. et al. (1984) <u>Journal Bacteriol.</u> 159:465-471.
<u>SACCHAROMYCES</u> <u>S. cerevisiae</u>	YEp24 YIp5 YRp17	Botstein and Davis in <u>Molecular Biology of the Yeast Saccharomyces</u> , Strathern, Jones, and Broach, eds., 1982, Cold Spring Harbor Laboratory.

It is to be understood that additional cloning vectors may now exist or will be discovered which have the above-identified properties and are therefore suitable for use in the present

invention. These vectors are also contemplated as being within the scope of the disclosed series of cloning vectors into which the portable DNA sequences may be introduced, along with any necessary operational elements, and which altered vector is then included within the scope of the present invention and would be capable of being used in the recombinant-DNA method set forth more fully below.

In addition to the above list, an E. coli vector system, as set forth in Example 2, is preferred in one embodiment as a cloning vector. Moreover, several vector plasmids which autonomously replicate in a broad range of Gram Negative bacteria are preferred for use as cloning vehicles in hosts of the genera Pseudomonas. These are described by Tait, R.C., Close, T.J., Lundquist, R.C., Hagiya, M., Rodriguez, R.L., and Kado, C.I. in Biotechnology, May, 1983, pp. 269-275; Panopoulos, N.J. in Genetic Engineering in the Plant Sciences, Praeger Publishers, New York, New York, pp. 163-185, (1981); and Sakaguchi, K. in Current Topic in Microbiology and Immunology 96:31-45, (1982), each of which is specifically incorporated herein by reference.

One particularly preferred construction employs the plasmid RSF1010 and derivatives thereof as described by Bagdasarian, M., Bagdasarian, M.M., Coleman, S., and Timmis, K.N. in Plasmids of Medical Environmental and Commercial Importance, Timmis, K.N. and Puhler, A. eds., Elsevier/North Holland Biomedical Press, (1979),

specifically incorporated herein by reference. The advantages of RSF1010 are that it is relatively small, high copy number plasmid which is readily transformed into and stably maintained in both E. coli and Pseudomonas species. In this system, it is preferred to use the Tac expression system as described for Escherichia, since it appears that the E. coli trp promoter is readily recognized by Pseudomonas RNA polymerase as set forth by Sakaguchi, K. in Current Topics in Microbiology and Immunology 96:31-45 (1982) and Gray, G.L., McKeown, K.A., Jones, A.J.S., Seeburg, P.H., and Heyneker, H.L. in Biotechnology Feb. 1984, pp. 161-165, both of which are specifically incorporated herein by reference. Transcriptional activity may be further maximized by requiring the exchange of the promoter with, e.g., an E. coli or P. aeruginosa trp promoter.

In a preferred embodiment, P. aeruginosa is transformed with vectors directing the synthesis of the metalloproteinase inhibitor as either an intracellular product or as a product coupled to leader sequences that will effect its processing and export from the cell. In this embodiment, these leader sequences are preferably selected from the group consisting of beta-lactamase, OmpA protein, the naturally occurring human signal peptide, and that of carboxypeptidase G2 from Pseudomonas. Translation may be coupled to translation initiation for any of the E. coli proteins as described in Example 2, as well as to initiation sites for any

000000000000000000000000

of the highly expressed proteins of the host to cause intracellular expression of the metalloproteinase inhibitor.

In those cases where restriction minus strains of a host Pseudomonas species are not available, transformation efficiency with plasmid constructs isolated from E. coli are poor. Therefore, passage of the Pseudomonas cloning vector through an r- m+ strain of another species prior to transformation of the desired host, as set forth in Bagdasarian, M., et al., Plasmids of Medical, Environmental and Commercial Importance, pp. 411-422, Timmis and Puhler eds., Elsevier/North Holland Biomedical Press (1979), specifically incorporated herein by reference, is desired.

Furthermore, a preferred expression system in hosts of the genera Bacillus involves using plasmid pUB110 as the cloning vehicle. As in other host vector systems, it is possible in Bacillus to express the metalloproteinase inhibitors of the present invention as either an intracellular or a secreted protein. The present embodiments include both systems. Shuttle vectors that replicate in both Bacillus and E. coli are available for constructing and testing various genes as described by Dubnau, D., Gryczan, T., Contente, S., and Shivakumar, A.G. in Genetic Engineering, Vol. 2, Setlow and Hollander eds., Plenum Press, New York, New York, pp. 115-131, (1980), specifically incorporated herein by reference. For the expression and secretion of

metalloproteinase inhibitors from B. subtilis, the signal sequence of alpha-amylase is preferably coupled to the coding region for the metalloproteinase inhibitor. For synthesis of intracellular metalloproteinase inhibitor, the portable DNA sequence will be translationally coupled to the ribosome binding site of the alpha-amylase leader sequence.

Transcription of either of these constructs is preferably directed by the alpha-amylase promoter or a derivative thereof. This derivative contains the RNA polymerase recognition sequence of the native alpha-amylase promoter but incorporates the lac operator region as well. Similar hybrid promoters constructed from the penicillinase gene promoter and the lac operator have been shown to function in Bacillus hosts in a regulatable fashion as set forth by Yansura, D.G. and Henner in Genetics and Biotechnology of Bacilli, Ganesan, A.T. and Hoch, J.A., eds., Academic Press, pp. 249-263, (1984), specifically incorporated by reference. The lacI gene of lacI<sup>q</sup> would also be included to effect regulation.

One preferred construction for expression in Clostridium is in plasmid pJUL2 described by Squires, C. H. et al in J. Bacteriol. 159:465-471 (1984), specifically incorporated herein by reference, transformed into C. perfringens by the method of Heefner, D. L. et al. as described in J. Bacteriol. 159:460-464 (1984), specifically incorporated herein by reference.

Transcription is directed by the promoter of the tetracycline resistance gene. Translation is coupled to the Shine-Dalgarno sequences of this same tet<sup>r</sup> gene in a manner strictly analogous to the procedures outlined above for vectors suitable for use in other hosts.

Maintenance of foreign DNA introduced into yeast can be effected in several ways (Botstein, D., and Davis, R. W., in The Molecular Biology of the Yeast Saccharomyces, Cold Spring Harbor Laboratory, Strathern, Jones and Broach, eds., pp. 607-636 (1982)). One preferred expression system for use with host organisms of the genus Saccharomyces harbors the anticollagenase gene on the 2 micron plasmid. The advantages of the 2 micron circle include relatively high copy number and stability when introduced into cir<sup>o</sup> strains. These vectors preferably incorporate the replication origin and at least one antibiotic resistance marker from pBR322 to allow replication and selection in E. coli. In addition, the plasmid will preferably have 2 micron sequences and the yeast LEU2 gene to serve the same purposes in LEU2 mutants of yeast.

The regulatable promoter from the yeast GALL gene will preferably be adapted to direct transcription of the portable DNA sequence gene. Translation of the portable DNA sequence in yeast will be coupled to the leader sequence that directs the secretion of yeast alpha-factor. This will cause formation of a fusion

protein which will be processed in yeast and result in secretion of a metalloproteinase inhibitor. Alternatively, a methionyl-malloproteinase inhibitor will be translated for inclusion within the cell.

It is anticipated that translation of mRNA coding for the metalloproteinase inhibitor in yeast will be more efficient with the preferred codon usage of yeast than with the sequence present in pUC8-Fic, as identified in Example 2, which has been tailored to the prokaryotic bias. For this reason, the portion of the 5' end of the portable DNA sequence beginning at the Tth111I site is preferably resynthesized. The new sequence favors the codons most frequently used in yeast. This new sequence preferably has the following nucleotide sequence:

Sub  
BIO

~~HgiAI~~

5' GAT CCG TGC ACT TGT GTT CCA CCA CAC  
          GC ACG TGA ACA CAA GGT GGT GTG  
  
          CCA CAA ACT GCT TTC TGT AAC TCT GAC C  
          GGT GTT TGA CGA AAG ACA TTG AGA CTG GA      3'

As will be seen from an examination of the individual cloning vectors and systems contained on the above list and description, various operational elements may be present in each of the preferred vectors of the present invention. It is contemplated any additional operational elements which may be required may be added to these vectors using methods known to those of

ordinary skill in the art, particularly in light of the teachings herein:

In practice, it is possible to construct each of these vectors in a way that allows them to be easily isolated, assembled, and interchanged. This facilitates assembly of numerous functional genes from combinations of these elements and the coding region of the metalloproteinase inhibitor. Further, many of these elements will be applicable in more than one host.

At least one origin of replication recognized by the contemplated host microorganism, along with at least one selectable marker and at least one promoter sequence capable of initiating transcription of the portable DNA sequence are contemplated as being included in these vectors. It is additionally contemplated that the vectors, in certain preferred embodiments, will contain DNA sequences capable of functioning as regulators ("operators"), and other DNA sequences capable of coding for regulator proteins. In preferred vectors of this series, the vectors additionally contain ribosome binding sites, transcription terminators and leader sequences.

These regulators, in one embodiment, will serve to prevent expression of the portable DNA sequence in the presence of certain environmental conditions and, in the presence of other environmental conditions, allow transcription and subsequent expression of the protein coded for by the portable DNA sequence. In

particular, it is preferred that regulatory segments be inserted into the vector such that expression of the portable DNA sequence will not occur in the absence of, for example, isopropylthio- $\beta$ -d-galactoside. In this situation, the transformed microorganisms containing the portable DNA may be grown to a desired density prior to initiation of the expression of the metalloproteinase inhibitor. In this embodiment, expression of the desired protease inhibitor is induced by addition of a substance to the microbial environment capable of causing expression of the DNA sequence after the desired density has been achieved.

Additionally, it is preferred that an appropriate secretory leader sequence be present, either in the vector or at the 5' end of the portable DNA sequence, the leader sequence being in a position which allows the leader sequence to be immediately adjacent to the initial portion of the nucleotide sequence capable of directing expression of the protease inhibitor without any intervening transcription or translation termination signals. The presence of the leader sequence is desired in part for one or more of the following reasons: 1) the presence of the leader sequence may facilitate host processing of the initial product to the mature recombinant metalloproteinase inhibitor; 2) the presence of the leader sequence may facilitate purification of the recombinant metalloproteinase inhibitors, through directing the metalloproteinase inhibitor out of the cell cytoplasm; 3) the

presence of the leader sequence may affect the ability of the recombinant metalloproteinase inhibitor to fold to its active structure through directing the metalloproteinase inhibitor out of the cell cytoplasm.

In particular, the leader sequence may direct cleavage of the initial translation product by a leader peptidase to remove the leader sequence and leave a polypeptide with the amino acid sequence which has the potential of metalloproteinase inhibitory activity. In some species of host microorganisms, the presence of the appropriate leader sequence will allow transport of the completed protein into the periplasmic space, as in the case of E. coli. In the case of certain yeasts and strains of Bacillus and Pseudomonas, the appropriate leader sequence will allow transport of the protein through the cell membrane and into the extracellular medium. In this situation, the protein may be purified from extracellular protein.

Thirdly, in the case of some of the metalloproteinase inhibitors prepared by the present invention, the presence of the leader sequence may be necessary to locate the completed protein in an environment where it may fold to assume its active structure, which structure possesses the appropriate metalloproteinase activity.

Additional operational elements include, but are not limited to, ribosome-binding sites and other DNA sequences necessary for

microbial expression of foreign proteins. The operational elements as discussed herein can be routinely selected by those of ordinary skill in the art in light of prior literature and the teachings contained herein. General examples of these operational elements are set forth in B. Lewin, Genes, Wiley & Sons, New York (1983), which is specifically incorporated herein by reference. Various examples of suitable operational elements may be found on the vectors discussed above and may be elucidated through review of the publications discussing the basic characteristics of the aforementioned vectors.

In one preferred embodiment of the present invention, an additional DNA sequence is located immediately preceding the portable DNA sequence which codes for the metalloproteinase inhibitor. The additional DNA sequence is capable of functioning as a translational coupler, i.e., it is a DNA sequence that encodes an RNA which serves to position ribosomes immediately adjacent to the ribosome binding site of the metalloproteinase inhibitor RNA with which it is contiguous.

Upon synthesis and/or isolation of all necessary and desired component parts of the above-discussed cloning vectors, the vectors are assembled by methods generally known to those of ordinary skill in the art. Assembly of such vectors is believed to be within the duties and tasks performed by those with ordinary skill in the art and, as such, is capable of being performed

without undue experimentation. For example, similar DNA sequences have been ligated into appropriate cloning vectors, as set forth in Schoner *et al.*, Proceedings of the National Academy of Sciences U.S.A., 81:5403-5407 (1984), which is specifically incorporated herein by reference.

In construction of the cloning vectors of the present invention, it should additionally be noted that multiple copies of the portable DNA sequence and its attendant operational elements may be inserted into each vector. In such an embodiment, the host organism would produce greater amounts per vector of the desired metalloproteinase inhibitor. The number of multiple copies of the DNA sequence which may be inserted into the vector is limited only by the ability of the resultant vector, due to its size, to be transferred into and replicated and transcribed in an appropriate host microorganism.

Additionally, it is preferred that the cloning vector contain a selectable marker, such as a drug resistance marker or other marker which causes expression of a selectable trait by the host microorganism. In a particularly preferred embodiment of the present invention, the gene for ampicillin resistance is included in vector pUC9-F5/237P10.

Such a drug resistance or other selectable marker is intended in part to facilitate in the selection of transformants.

Additionally, the presence of such a selectable marker on the

cloning vector may be of use in keeping contaminating microorganisms from multiplying in the culture medium. In this embodiment, such a pure culture of the transformed host microorganisms would be obtained by culturing the microorganisms under conditions which require the induced phenotype for survival.

It is noted that, in preferred embodiment, it is also desirable to reconstruct the 3' end of the coding region to allow assembly with 3' non-translated sequences. Included among these non-translated sequences are those which stabilize the mRNA or enhance its transcription and those that provide strong transcriptional termination signals which may stabilize the vector as they are identified by Gentz, R., Langner, A., Chang, A.C.Y., Cohen, S.H., and Bujard, H. in Proc. Natl. Acad. Sci. USA 78:4936-4940 (1981), specifically incorporated herein by reference.

This invention also relates to a recombinant-DNA method for the production of metallproteinase inhibitors. Generally, this method includes:

- (a) preparation of a portable DNA sequence capable of directing a host microorganism to produce a protein having metalloproteinase inhibitor activity;
- (b) cloning the portable DNA sequence into a vector capable of being transferred into and replicating in a host microorganism, such vector containing operational elements for the portable DNA sequence;

LAW OFFICES  
FINNEGAN, HENDERSON  
FARABOW, GARRETT  
& DUNNER  
1775 K STREET, N.W.  
WASHINGTON, D.C. 20006  
(202) 293-6850

(c) transferring the vector containing the portable DNA sequence and operational elements into a host microorganism capable of expressing the metalloproteinase inhibitor protein;

(d) culturing the host microorganism under conditions appropriate for amplification of the vector and expression of the inhibitor; and

(e) in either order:

(i) harvesting the inhibitor; and

(ii) causing the inhibitor to assume an active, tertiary structure whereby it possesses metalloproteinase inhibitor activity.

*Sub BII* In this method, the portable DNA sequences are those synthetic or naturally-occurring polynucleotides described above.

In a preferred embodiment of the present method, the portable DNA sequence has the nucleotide sequence as follows:

10	20	30	40	50	60
GTTGTTGCTG	TGGCTGATAG	CCCCAGCAGG	GCCTGCACCT	GTGTCCCACC	CCACCCACAG
70	80	90	100	110	120
ACGGCCTTCT	GCAATTCCGA	CCTCGTCATC	AGGGCCAAGT	TCGTGGGGAC	ACCAGAAGTC
130	140	150	160	170	180
AACCAGACCA	CCTTATAACCA	GCGTTATGAG	ATCAAGATGA	CCAAGATGTA	TAAAGGGTTC
190	200	210	220	230	240
CAAGCCTTAG	GGGATGCCGC	TGACATCCGG	TTCGTCTACA	CCCCCGCCAT	GGAGAGTGTGTC
250	260	270	280	290	300
TGCGGATACT	TCCACAGGTC	CCACAAACCGC	AGCGAGGAGT	TTCTCATTGC	TGGAAAACGT

310	320	330	340	350	360
CAGGATGGAC TCTTGACAT CACTACCTGC AGTTTCGTGG CTCCCTGGAA CAGCCTGAGC					
370	380	390	400	410	420
TTAGCTCAGC GCCGGGGCTT CACCAAGACC TACACTGTTG GCTGTGAGGA ATGCACAGTG					
430	440	450	460	470	480
TTTCCCTGTT TATCCATCCC CTGCAAATG CAGAGTGGCA CTCATTGCTT GTGGACGGAC					
490	500	510	520	530	540
CAGCTCCTCC AAGGCTCTGA AAAGGGCTTC CAGTCCCGTC ACCTTGCCCTG CCTGCCTCGG					
550	560	570	580	590	600
GAGCCAGGGC TGTGCACCTG GCAGTCCCTG CGGTCCCAGA TAGCCTGAAT CCTGCCCGGA					
610	620	630	640	650	660
GTGGAAGCTG AAGCCTGCAC AGTGTCCACC CTGTTCCAC TCCCATCTTT CTTCCGGACA					
670	680	690	700		
ATGAAATAAA GAGTTACAC CCAGCAAAAA AAAAAAGGAA TTC					

The vectors contemplated as being useful in the present method are those described above. In a preferred embodiment, the cloning vector pUC9-F5/237P10 is used in the disclosed method.

The vector thus obtained is then transferred into the appropriate host microorganism. It is believed that any microorganism having the ability to take up exogenous DNA and express those genes and attendant operational elements may be chosen. It is preferred that the host microorganism be an anaerobe, facultative anaerobe or aerobe. Particular hosts which may be preferable for use in this method include yeasts and bacteria. Specific yeasts include those of the genus Saccharomyces, and especially Saccharomyces cerevisiae.

Specific bacteria include those of the genera Bacillus and Escherichia and Pseudomonas. Various other preferred hosts are

SEARCHED  
INDEXED  
SERIALIZED  
FILED

set forth in Table I, supra. In other, alternatively preferred embodiments of the present invention, Bacillus subtilis, Escherichia coli or Pseudomonas aeruginosa are selected as the host microorganisms.

After a host organism has been chosen, the vector is transferred into the host organism using methods generally known by those of ordinary skill in the art. Examples of such methods may be found in Advanced Bacterial Genetics by R. W. Davis et al., Cold Spring Harbor Press, Cold Spring Harbor, New York, (1980), which is specifically incorporated herein by reference. It is preferred, in one embodiment, that the transformation occur at low temperatures, as temperature regulation is contemplated as a means of regulating gene expression through the use of operational elements as set forth above. In another embodiment, if osmolar regulators have been inserted into the vector, regulation of the salt concentrations during the transformation would be required to insure appropriate control of the synthetic genes.

If it is contemplated that the recombinant metalloproteinase inhibitors will ultimately be expressed in yeast, it is preferred that the cloning vector first be transferred into Escherichia coli, where the vector would be allowed to replicate and from which the vector would be obtained and purified after amplification. The vector would then be transferred into the yeast for ultimate expression of the metalloproteinase inhibitor.

The host microorganisms are cultured under conditions appropriate for the expression of the metalloproteinase inhibitor. These conditions are generally specific for the host organism, and are readily determined by one of ordinary skill in the art, in light of the published literature regarding the growth conditions for such organisms, for example Berkeley's Manual of Determinative Bacteriology, 8th Ed., Williams & Wilkins Company, Baltimore, Maryland, which is specifically incorporated herein by reference.

Any conditions necessary for the regulation of the expression of the DNA sequence, dependent upon any operational elements inserted into or present in the vector, would be in effect at the transformation and culturing stages. In one embodiment, the cells are grown to a high density in the presence of appropriate regulatory conditions which inhibit the expression of the DNA sequence. When optimal cell density is approached, the environmental conditions are altered to those appropriate for expression of the portable DNA sequence. It is thus contemplated that the production of the metalloproteinase inhibitor will occur in a time span subsequent to the growth of the host cells to near optimal density, and that the resultant metalloproteinase inhibitor will be harvested at some time after the regulatory conditions necessary for its expression were induced.

In a preferred embodiment of the present invention, the recombinant metalloproteinase inhibitor is purified subsequent to harvesting and prior to assumption of its active structure. This embodiment is preferred as the inventors believe that recovery of a high yield of re-folded protein is facilitated if the protein is first purified. However, in one preferred, alternate embodiment, the metalloproteinase inhibitor may be allowed re-fold to assume its active structure prior to purification. In yet another preferred, alternate embodiment, the metalloproteinase inhibitor is caused to assume its re-folded, active state upon recovery from the culturing medium.

*Sub B12*

In certain circumstances, the metalloproteinase inhibitor will assume its proper, active structure upon expression in the host microorganism and transport of the protein through the cell wall or membrane or into the periplasmic space. This will generally occur if DNA coding for an appropriate leader sequence has been linked to the DNA coding for the recombinant protein. The preferred metalloproteinase inhibitors of the present invention will assume their mature, active form upon translocation out of the inner cell membrane. The structures of numerous signal peptides have been published, for example by Marion E.E. Watson in Nuc. Acid Res. 12:515-5164, 1984, specifically incorporated herein by reference. It is intended that these leader sequences, together with portable DNA, will direct intracellular production

B12  
series

of a fusion protein which will be transported through the cell membrane and will have the leader sequence portion cleaved upon release from the cell.

In a preferred embodiment, the signal peptide of the E.coli OmpA protein is used as a leader sequence and is located in a position contiguous with the portable DNA sequence coding for the metalloproteinase inhibitor structure.

Additionally preferred leader sequences include those of beta-lactamase, carboxypeptidase G2 and the human signal protein. These and other leader sequences are described.

If the metalloproteinase inhibitor does not assume its proper, active structure, any disulfide bonds which have formed and/or any noncovalent interactions which have occurred will first be disrupted by denaturing and reducing agents, for example, guanidinium chloride and  $\beta$ -mercaptoethanol, before the metalloproteinase inhibitor is allowed to assume its active structure following dilution and oxidation of these agents under controlled conditions.

The transcription terminators contemplated herein serve to stabilize the vector. In particular, those sequences as described by Gentz et al., in Proc. Natl. Acad. Sci. USA 78: 4936-4940 (1981), specifically incorporated herein by reference, are contemplated for use in the present invention.

It is to be understood that application of the teachings of the present invention to a specific problem or environment will be within the capabilities of one having ordinary skill in the art in light of the teachings contained herein. Examples of the products of the present invention and representative processes for their isolation and manufacture appear in the following examples.

#### EXAMPLES

##### EXAMPLE 1

sub B13

###### Preparation of Poly(A) RNA from HEF-SA Fibroblasts

HEF-SA cells were grown to near confluence in 75 cm<sup>2</sup> T-flasks. Cells were washed twice in Dulbecco's phosphate buffered saline solution and harvested by the addition of 2 ml of 10 mM Tris, pH 7.5 containing 1% w/v SDS (obtained from BDH chemicals, Ltd., Poole, England), 5 mM EDTA and 20 ug/ml protease K (obtained from Boehringer Mannheim Biochemicals, Indianapolis, Indiana). Each flask was subsequently washed with an additional milliliter of this same solution.

The pooled aliquots from the cell harvest were made to 70 ug/ml in protease K and incubated at 40°C for 45 minutes. The proteolyzed solution was brought to a NaCl concentration of 150 mM by the addition of 5 M stock and subsequently extracted with an equal volume of phenol:chloroform 1:1. The aqueous phase was reextracted with an equal volume of chloroform. Two volumes of

202529

ethanol were added to the aqueous phase and incubated overnight at -20°C. The precipitated nucleic acids were recovered by centrifugation at 17,500 xg for 10 minutes in a Beckman J2-21 centrifuge, Beckman Instruments, Palo Alto, California, and were redissolved in 25 ml of 0.1% w/v SDS. This solution was again extracted with an equal volume of chloroform. The aqueous phase was added to two volumes of cold ethanol and kept at -20°C for 2 hours. The precipitate was collected by centrifugation at 10,000 xg for 15 minutes and redissolved in 10 ml of 1 mM Tris, 0.5 mM EDTA, 0.1% SDS, pH 7.5. RNA was precipitated from this solution by the addition of 10 ml of 4 M LiCl, 20 mM NaOAc, pH 5.0 and incubated at -20°C for 18 hours. The precipitate was again recovered by centrifugation and washed twice with 2 M LiCl before redissolving in 1 mM Tris, 0.5 mM EDTA, 0.1% SDS, pH 7.5. This solution was stored at -70°C.

#### Chromatography on Oligo dT Cellulose

Total cellular RNA prepared as above was ethanol precipitated and redissolved in 0.5 M NaCl. Five ml of RNA at 0.45 mg/ml were applied to a 1 ml column of washed type VII oligo dT cellulose (obtained from PL Biochemicals, Milwaukee, Wisconsin). The column was then washed with 10 ml of 0.5 M NaCl and eluted with 2.0 ml of sterile H<sub>2</sub>O. The eluted poly(A<sup>+</sup>) fraction of RNA was ethanol precipitated and dissolved to give a 1 mg/ml solution in 1 mM Tris, 0.1 mM EDTA, pH 8.0. This was stored at -70°C.

cDNA Synthesis

Poly(A<sup>+</sup>) RNA was primed with oligo dT (obtained from PL Biochemicals, Milwaukee, Wisconsin) to serve as a template for cDNA synthesis by AMV reverse transcriptase (obtained from Life Sciences, Inc., St. Petersburg, Florida). Following the synthesis reaction, the RNA was hydrolyzed by the addition of 0.1 volume of 3 N NaOH and incubated at 67°C for 10 minutes. The solution was then neutralized and the cDNA purified by gel filtration chromatography on biogel A 1.5 (obtained from BioRad Laboratories, Richmond, California) in a 0.7x25 cm column in a 10 mM Tris, 5 mM EDTA, and 1% SDS, pH 7.5 solution. Fractions containing cDNA were pooled and concentrated by ethanol precipitation. The cDNA was dG tailed and purified by gel filtration using the procedure set forth above. Second strand synthesis was primed with oligo dC and polymerized in an initial reaction with the large (Klenow) fragment of DNA polymerase (obtained from Boehringer Mannheim). Following second strand synthesis, E. coli DNA polymerase I (obtained from Boehringer Mannheim) was added and incubation continued to form blunt ends. The double stranded cDNA was again purified by chromatography. EcoRI restriction sites within the cDNAs were modified by the action of EcoRI methylase, obtained from New England Biolabs, Beverly, Massachusetts. The cDNA was again purified and ligated to synthetic EcoRI linkers. Finally, the ends were then trimmed with the

endonuclease and the cDNA purified by gel filtration. This DNA was ligated into a unique EcoRI site in lambda gt10 DNA packaged in vitro and used to infect E. coli strain hflA according to the method set forth by Huynh, T.V., Young, R.A., and Davis, R.W., in DNA Cloning Techniques, A Practical Approach (ed. Glover, D.M.) (IRL Press Oxford), in press, specifically incorporated herein by reference. Approximately 25,000 recombinants were amplified in this manner.

#### Screening

Recombinant-phage-containing sequences of interest were selected by their preferential hybridization to synthetic oligonucleotides encoding portions of the primary structure of the desired metalloproteinase inhibitor, hereinafter referred to as FIBAC. These portions of the protein sequence correspond in part to those set forth in the published literature by Stricklin, G.P. and Welgus, H.G., J. Biol. Chem. 258: 12252-12258 (1983), specifically incorporated herein by reference. Recombinant phage were used to infect E. coli strain hflA and plated at a density of approximately  $2 \times 10^3$  pfu/150 mm petri dish. Phage were blotted onto nitrocellulose filters (BA85, Schleicher & Schuell Inc., Keene, New Hampshire), and DNA was denatured and fixed essentially as described by Benton and Davis in Science 196:180-182 (1979) specifically incorporated herein by reference.

Using that procedure, the filters were treated sequentially for 10-15 minutes each in 0.5 M NaCl, then 1.0 M Tris, 1.5 M NaCl pH 8.0, and finally submerged in 2x SSPE. (2x SSPE is 0.36 M NaCl, 20 mM NaH<sub>2</sub>PO<sub>4</sub>, 2 mM EDTA pH 7.4). Filters were blotted dry and baked 75°-80° for 3-4 hours. Duplicate filters were made of each plate. Filters were prehybridized for 1-3 hours at 37° in 5x SSPE containing 0.1x SET, 0.15% NaPPI, and 1x Denhardts solutions. Filters were then hybridized for 72 hours at 37° in this same solution containing  $5 \times 10^5$  cpm/ml of 5' end-labeled 51-mer oligonucleotide specific activity approximately  $10^6$  cpm/pmole). Following hybridization, filters were washed six times in 5x SSPE containing 0.1x SET and 0.05% sodium pyrophosphate at 37°, then three times in 2x SSPE at 21°. These were then blotted dry and autoradiographed on Kodak XAR-5 film at -70° with a Kodak lightening-plus intensifying screen. Signals clearly visible from duplicate filters were used to pick phage for plaque purification. Filter preparations and hybridization procedures for plaque purification steps were the same as above. The washing procedure was simplified to 6 changes of 2x SSPE at 37°. Six isolates purified by repetitive plating were then arranged on a single lawn of E. coli strain C600 for testing with subsequent probes.

Preferential hybridization of the 17-mer to each of the isolates (as opposed to control plaques) was observed under a

condition identical to that used for plaque purification. Probe C was used in a similar test, except that the SSPE concentration during hybridization was reduced to 4x. Again, each of the isolates demonstrated stronger hybridization to the probe than did control plaques.

Phage Purification and cDNA Characterization

Quantities of each of the six isolated phage were made by the plate stock technique and purified by serial CsCl block gradient centrifugation. DNA was extracted from these by dialysis against 50% formamide as described by Davis, R.W., Botstein, D., Roth, J.R., in A Manual for Genetic Engineering: Advanced Bacterial Genetics, 1980, Cold Spring Harbor Laboratory, specifically incorporated herein by reference. DNA from each of the isolates was digested with EcoRI and the products were analyzed by agarose gel electrophoresis. The insert from one of the larger clones, lambda FIBAC 5, was found to lack internal sites for SalI, HindIII, BamHI, and EcoRI. The cDNA insert was released from lambda FIBAC 5 DNA and the lambda arms digested by co-digesting with these four enzymes. The fragments were then ethanol-precipitated and ligated into the EcoRI site of plasmid pUC9 without further purification. These plasmids were then used to transform E. coli strain JM83. Transformants were selected on ampicillin containing plates. Plasmids from several transformants were purified and characterized on the basis of the

EcoRI digestion products. One was selected which had an insert co-migrating with the insert from lambda FIBAC 5 on agarose gel electrophoresis. This plasmid has been named pUC9-F5/237P10.

Mapping and Subcloning

The insert in pUC9-F5/237P10 was mapped with respect to internal PstI sites. Double digests with EcoRI and PstI demonstrated three internal PstI recognition sites. The entire insert and the component pieces were subcloned into M13 bacteriophage mp19 and mp18, respectively. Sequencing of the pieces was performed by the dideoxynucleotide method described by Sanger *et al.* in Sanger, F., Nicklen, S., and Coulson, A.R., Proc. Natl. Acad. Sci. USA 74:5463-5467 (1977), specifically incorporated herein by reference.

The sequence of the DNA insert from pUC9-F5/237P10 showed an open reading frame which encodes the primary structure of a mature fibroblast collagenase inhibitor biologically equivalent to that isolable from human skin fibroblasts. The salient features of the sequence are:

- (1) The insert is flanked by EcoRI restriction sites and by G/C and A/T homopolymeric tracts consistent with the cloning methodology;
- (2) The coding strand is presented in the 5' to 3' convention with poly C at the 5' end and poly A at the 3' end, again consistent with the techniques employed;
- (3) If the first G in the sequence GTTGTG immediately adjacent to the 3' end of the poly C tract is considered as nucleotide 1, then an open reading frame is presented which encodes

the primary structure of the mature human fibroblast collagenase inhibitor beginning at nucleotide 34 and continuing through nucleotide 585;

- (4) The termination codon TGA at nucleotides 586 through 588 defines the carboxy terminus of the translation product which is the same as that of the mature protein;
- (5) Nucleotides 1 through 33 define an amino acid sequence which is not found in the primary structure of the processed protein, but which is probably a portion of a leader peptide characteristic of secreted proteins;
- (6) The three internal PstI sites have as their first base nucleotides 298, 327, and 448;
- (7) There is a single recognition sequence for the restriction enzyme Tth11I beginning at nucleotide 78; and
- (8) There is a single recognition sequence for the restriction endonuclease NcoI beginning at nucleotide 227.

The sequence of nucleotides 1 through 703 and restriction site analysis are shown.

	#	SITES	FRAGMENTS	FRAGMENTS	ENDS
ACC 1 (GTVWAC)	1	214	495 (69.8) 214 (30.2)	214 1	709 214
ALU 1 (AGCT)	4	358 363 482 606	358 (50.5) 124 (17.5) 119 (16.8) 103 (14.5) 5 ( 0.7)	1 482 363 606 358	358 606 482 709 363
AVA 1 (CQCGPG)	1	536	536 (75.6) 173 (24.4)	1 536	536 709
AVA 2 (GGRCC)	3	257 477 572	257 (36.2) 220 (31.0) 137 (19.3) 95 (13.4)	1 257 572 477	257 477 709 572
BBV 1 (GCTGC)	1	269	440 (62.1) 269 (37.9)	269 1	709 269
BST N1 (CCRGG)	3	344 544 557	344 (48.5) 200 (28.2) 152 (21.4) 13 ( 1.8)	1 344 557 544	344 544 709 557
DDE 1 (CTNAG)	4	186 355 360 365	344 (48.5) 186 (26.2) 169 (23.8) 5 ( 0.7) 5 ( 0.7)	365 1 186 360 355	709 186 355 365 360
ECO R1 (GAATTC)	1	698	698 (98.4) 11 ( 1.6)	1 698	698 709
FNU4H 1 (GCNGC)	2	196 269	440 (62.1) 196 (27.6) 73 (10.3)	269 1 196	709 196 269

LAW OFFICES  
 FINNEGAN, HENDERSON  
 FARABOW, GARRETT  
 & DUNNER  
 1775 K STREET, N.W.  
 WASHINGTON, D.C. 20006  
 (202) 293-6650

	#	SITES	FRAGMENTS	FRAGMENTS	ENDS
FOK 1 (GGATG)	4	192 204 303 435	274 (38.6) 192 (27.1) 132 (18.6) 99 (14.0) 12 ( 1.7)	435 1 303 204 192	709 192 435 303 204
HAE 2 (PGCGCQ)	1	368	368 (51.9) 341 (48.1)	1 368	368 709
HAE 3 (GGCC)	3	30 63 93	616 (86.9) 33 ( 4.7) 30 ( 4.2) 30 ( 4.2)	93 30 63 1	709 63 93 30
HGI A1 (GRGCRC)	1	552	552 (77.9) 157 (22.1)	1 552	552 709
HHA 1 (GCGC)	1	369	369 (52.0) 340 (48.0)	1 369	369 709
HINC 2 (GTQPAC)	1	118	591 (83.4) 118 (16.6)	118 1	709 118
HINF 1 (GANTC)	2	308 587	308 (43.4) 279 (39.4) 122 (17.2)	1 308 587	308 587 709
HPA 2 (CCGG)	4	207 372 596 654	224 (31.6) 207 (29.2) 165 (23.3) 58 ( 8.2) 55 ( 7.8)	372 1 207 596 654	596 207 372 654 709
HPH 1 (GGTGA)	2	380 519	380 (53.6) 190 (26.8) 139 (19.6)	1 519 380	380 709 519

LAW OFFICES  
 FINNEGAN, HENDERSON  
 FARABOW, GARRETT  
 & DUNNER  
 1775 K STREET, N.W.  
 WASHINGTON, D.C. 20006  
 (202) 293-6650

	#	SITES	FRAGMENTS	FRAGMENTS	ENDS
MBO 2 (GAAGA)	1	650	650 (91.7) 59 ( 8.3)	1 650	650 709
MNL 1 (CCTC)	5	81 274 406 486 535	193 (27.2) 174 (24.5) 132 (18.6) 81 (11.4) 80 (11.3) 49 ( 6.9)	81 535 274 1 406 486	274 709 406 81 486 535
MST 2 (CCTNAGG)	1	185	524 (73.9) 185 (26.1)	185 1	709 185
NCI 1 (CCSGG)	2	372 595	372 (52.5) 223 (31.5) 114 (16.1)	1 372 595	372 595 709
NCO 1 (CCATGG)	1	227	482 (68.0) 227 (32.0)	227 1	709 227
NSP B2 (CVGCWG)	1	197	512 (72.2) 197 (27.8)	197 1	709 197
PST 1 (CTGCAG)	3	298 327 448	298 (42.0) 261 (36.8) 121 (17.1) 29 ( 4.1)	1 448 327 298	298 709 448 327
SAU 1 (CCTNAGG)	1	185	524 (73.9) 185 (26.1)	185 1	709 185
SAU 3A (GATC)	1	150	559 (78.8) 150 (21.2)	150 1	709 150

LAW OFFICES  
 FINNEGAN, HENDERSON  
 FARABOW, GARRETT  
 & DUNNER  
 1775 K STREET, N.W.  
 WASHINGTON, D.C. 20006  
 (202) 293-6850

	#	SITES	FRAGMENTS	FRAGMENTS	ENDS
SAU96 1 (GGNCC)	5	29 92 257 477 572	220 (31.0) 165 (23.3) 137 (19.3) 95 (13.4) 63 ( 8.9)	257 92 572 477 29	477 257 709 572 92
SCR F1 (CCNGG)	5		29 ( 4.1)	1	29
SFA N1 (GATGC)	1	344 372 544 557 595	344 (48.5) 172 (24.3) 114 (16.1) 38 ( 5.4) 28 ( 3.9)	1 372 595 557 344	344 544 709 595 372
TTH111 1 (GACNNNGTC)	1	193	516 (72.8) 193 (27.2)	193 1	709 193
		79	630 (88.9) 79 (11.1)	79 1	709 79

LAW OFFICES  
 FINNEGAN, HENDERSON  
 FARABOW, GARRETT  
 & DUNNER  
 1775 K STREET, N.W.  
 WASHINGTON, D.C. 20006  
 (202) 293-6880

The following do not appear:

AAT	2	AFL	2	AFL	3	AHA	3
APA	1	ASU	2	AVA	3	AVR	2
BAL	1	BAM	H1	BCL	1	BGL	1
BGL	2	BIN	1	BSSH	1	BST	E2
CFR	1	CLA	1	ECO	R5	FNUD	2
GDI	2	HAE	1	HGA	1	HGI	C1
HGI	D1	HGI	J2	HIND	3	HPA	1
KPN	1	MLU	1	MST	1	NAE	1
NAR	1	NDE	1	NRU	1	NSP	C1
PVU	1	PVU	2	RRU	1	RSA	1
SAC	1	SAC	2	SAL	1	SMA	1
SNA	1	SPH	1	STU	1	TAQ	1
XBA	1	XHO	1	XHO	2	XMA	3
XMN	1						

10            20            30            40            50            60  
GTTGTTGCTG TGGCTGATAG CCCCAGCAGG GCCTGCACCT GTGTCCCACC CCACCCACAG

SH  
AA  
UE  
13

70            80            90            100          110          120  
ACGGCCTTCT GCAATTCCGA CCTCGTCATC AGGGCCAAGT TCGTGGGGAC ACCAGAACGTC

H	T	M	SH		H
A	T	N	AA		I
E	H	L	UE		N
3	1	1	13		2

130          140          150          160          170          180  
AACCAGACCA CCTTATACCA GCGTTATGAG ATCAAGATGA CCAAGATGTA TAAAGGGTTC

S  
A  
U  
A

190          200          210          220          230          240  
CAAGCCTTAG GGGATGCCGC TGACATCCGG TTCGTCTACA CCCCGCCAT GGAGAGTGTC

SD	FS	FN	F	H	A	N
AD	OF	NS	O	P	C	C
UE	KA	UP	K	A	C	O
11	11	12	1	2	1	1

250	260	270	280	290	300
TGCGGATACT	TCCACAGGTC	CCACAACCGC	AGCGAGGGAGT	TTCTCATATTGC	TGGAAAACGT
A	B	M			P
V	B	N			S
A	V	L			T
2	1	1			1
310	320	330	340	350	360
CAGGATGGAC	TCTTGCACAT	CACTACCTGC	AGTTTCGTGG	CTCCCTGGAA	CAGCCTGAGC
F	H	P		B	D A D
O	I	S		S	D L D
K	N	T		T	E U E
1	1	1		1	1 1 1
370	380	390	400	410	420
TTAGCTCAGC	GCCGGGGCTT	CACCAAGACC	TACACTGTTG	GCTGTGAGGA	ATGCACAGTG
A D	HH	N H		M	
L D	AH	C P		N	
U E	EA	I H		L	
1 I	21	1		1	
430	440	450	460	470	480
TTTCCCTGTT	TATCCATCCC	CTGCAAACGT	CAGAGTGGCA	CTCATTGCTT	GTGGACGGAC
F		P			A
O		S			V
K		T			A
1		1			2
490	500	510	520	530	540
CAGCTCCTCC	AAGGCTCTGA	AAAGGGCTTC	CAGTCCCGTC	ACCTTGCTG	CCTGCCTCGG
A M		H			MA
L N		P			NV
U L		H			LA
1 1		1			11
550	560	570	580	590	600
GAGCCAGGGC	TGTGCACCTG	GCAGTCCCTG	CGGTCCCAGA	TAGCCTGAAT	CCTGCCCGGA
B H B		A H			NH
S G S		V I			CP
T I T		A N			IA
1 1 1		2 1			12
610	620	630	640	650	660
GTGGAAGCTG	AAGCCTGCAC	AGTGTCCACC	CTGTTCCCAC	TCCCATCTT	CTTCCGGACA
A				M H	
L				B P	
U				O A	
1				2 2	

LAW OFFICES  
 FINNEGAN, HENDERSON  
 FARABOW, GARRETT  
 & DUNNER  
 1775 K STREET, N.W.  
 WASHINGTON, D.C. 20006  
 (202) 293-6850

## EXAMPLE 2-EXPRESSION OF COLLAGENASE INHIBITOR IN E. COLI

In this Example, a preferred method of coupling a preferred portable DNA sequence to the 5' end of the cloned cDNA is set forth. This involves making a nucleolytic cleavage at a specified point within the coding sequence and reconstructing the desired portion of the coding sequence by means of synthetic oligonucleotides in a manner that allows its excision and recombination (i.e., by incorporating useful restriction sites).

Trimming the 5' end of the coding region will be accomplished by synthesizing both strands of the DNA extending from the Tth111I site in the 5' direction and ending in a BamHI overhang. This synthetic oligonucleotide, referred to as FIBAC A, has the following features:

- (1) Codon selection has been biased toward those most frequently found in the genes of highly expressed bacterial proteins;
- (2) A methionine codon from which to initiate translation has been provided immediately upstream from the cysteine which begins the coding region of human processed FIBAC;
- (3) The spacing of the BamHI site to the methionine codon is such that when cloned into pUC8, the coding region of FIBAC will be in-frame with the 5' end of the beta-galactosidase gene;

7/18/86

) An in-frame stop codon and Shine Dalgarno sequence are also presented. Translation of this frame for the amino terminal portion of the beta-galactosidase is terminated at the TAA codon, and translation of FIBAC should be initiated at the following ATG;

(5) Codons have been selected to create a H<sub>q</sub>I site beginning with the G in the FIBAC initiation codon; and

(6) There is a PvuI site separated by one base from the 3' end of the BamHI sequence.

The structure of FIBAC A is

*Sub B14*  
GA TCC GCG ATC GGA GTG TAA GAA ATG TGC ACT  
G CGC TAG CCT CAG ATT CTT TAC ACG TGA

TGC GTT CCG CCG CAT CCG CAG ACT GCT TTC  
ACG CAA GGC GGC GTA GGC GTC TGA CGA AAG

TGC AAC TCT GAC C  
ACG TTG AGA CTG GA

FIBAC A is synthesized using the ABI DNA synthesizer (Foster

City, California) as a series of four component oligonucleotides.

*Sub B15*

Component oligonucleotide FA1 is:  
GATCC GCGAT CGGAG TGTAA GAAAT GTGCA CTTGC

*Sub B16*

Component oligonucleotide FA2 is:  
GGAACG CAAGT GCACA TTTCT TACAC TCCGA TCGCG

*Sub B17*

Component oligonucleotide FA3 is:  
GTTC CGCCG CATCC GCAGA CTGCT TTCTG CAACT CTGAC C

*Sub B18*

Component oligonucleotide FA4 is:  
AGGTC AGAGT TGCA~~G~~ AAAGC AGTCT GCGGA TGCGG C

The remainder of the coding portion of the FIBAC gene is isolated as the 3' Tth11I to EcoRI fragment generated by a double digest of pUC9-F5/237P10 with these enzymes.

A synthetic linker is made to couple the 3' end of the Tth11I to EcoRI fragment to a SalI site. These oligonucleotide

will be designed to recreate the EcoI site and destroy the EcoRI site. The linker is comprised of the oligonucleotides linker A1 and linker A2.

(Seq ID No:16)

Linker A1 is: AATTGGCAG

(Seq ID No:17)

Linker A2 is: TCGACTGCC

These oligonucleotides and oligonucleotides FA1-FA4 are kinased separately and annealed in equal molar ratios with the Tth111I to EcoRI 3' end of the cDNA and BamHI/SalI cut mp19RF DNA. The ligated DNA is used to transfect JM105. Plaques are picked by their color in the presence of IPTG and X-gal and by hybridization to oligonucleotide FA2. Several positive plaques are to be sequenced. Those containing the designed sequence are subcloned into BamHI/SalI digested pUC8. Translation of the FIBAC gene in this construct is coupled to translation initiated for beta-galactosidase. This expression vector is referred to as pUC8-Fic.

Coupling translation of FIBAC to translation initiated for other highly expressed proteins is similarly arranged. For example, a portion of the OmpA gene which contains the Shine-Dalgarno and initiator methionine sequences has been synthesized. This sequence encodes the entire signal peptide of OmpA protein and had convenient restriction sites, including those for EcoRI, EcoRV, PvuI, and StuI.

*Just B19*

The sequence of the sense strand

10	20	30	40	50	60
GAATTGATA	TCTCGTTGGA	GATATTGATG	ACGTATTTG	GATGATAACG	AGGCGCAAA
E T E			F	M H	
C A C			O	N H	
O Q O			K	L A	
1 1 5			1	1 1	

  

70	80	90	100	110
AATGAAAAAG	ACAGCTATCG	CGATCGCAGT	GGCACTGGCT	GGTTTCGCTA CCGTA
A	NF PS			
L	RN VA			
U	UU UU			
1	12 1A			

  

120	130
GCGCA	GGCCTCTGGT AAAAGCTT
H S H M	HA
H T A N	IL
A U E L	NU
1 1 3 1	31

This sequence is hereinafter referred to as OmpA leader.

Coupling the translation of FIBAC to OmpA is accomplished by cutting the pUC8-Fic with PvuI and SalI and isolating the coding region. This, together with the EcoRI to PvuI fragment isolated from OmpA leader, will be cloned into EcoRI/SalI-cut pUC8. As in the prior example, transcription is driven by the lac promoter and regulated by the lac I gene product at the lac operator. This FIBAC expression vector is referred to as pUC8-F/OmpAic.

To effect the translocation of FIBAC out of the inner cell membrane, an appropriate leader sequence is added to the amino terminus of FIBAC. The protein thus produced will be translocated and processed to yield the mature form.

To effect such a translocation, a FIBAC gene encoding the signal peptide of the E. coli OmpA protein continuous with the structural region of FIBAC is created. This particular FIBAC gene necessitates having in frame stop codons at the 5' end of the FIBAC coding region changed. To accomplish this, the portion of the 5' coding region from pUC8-Fic that extends from the H<sub>Q</sub>iAI site to the N<sub>C</sub>OI site is isolated. Upstream sequences are resynthesized as a linker having cohesive ends from BamHI and H<sub>Q</sub>iAI and containing an internal S<sub>T</sub>uI site. This is synthesized as two oligonucleotides, linker B1 and linker B2.

Linker B1 is: GATCCCAGGCCTGCA  
(SEQ ID NO: 1)

Linker B2 is: GGCCTGG  
(SEQ ID NO: 2)

Linkers B1 and B2 are kinased separately and annealed in equal molar ratios with the H<sub>Q</sub>iAI to N<sub>C</sub>OI fragment described above and BamHI/N<sub>C</sub>OI cut pUC8-Fic. The resulting construct has the coding sequence of FIBAC in frame with the translation of the amino terminus of beta-galactosidase. Translation of this sequence forms a fusion protein with FIBAC. This plasmid is referred to as pUC8-Ff.

Attaching the OmpA leader sequences to the coding region of FIBAC is accomplished by ligating EcoRI/S<sub>T</sub>uI cut pUC8-Ff with an excess of the purified EcoRI to S<sub>T</sub>uI fragment of OmpA leader. Following transformation, plasmids from several colonies will be characterized by hybridization. Those that have incorporated the

OmpA leader fragment are characterized further to verify the structure. This plasmid, pUC8-F OmpAl, will direct the synthesis of a fusion protein beginning in the signal peptide of the E. coli OmpA protein and ending in human FIBAC. The signals present in the OmpA portion of the protein effect the protein's export from the cytoplasm and appropriate cleavage from the primary structure of FIBAC.

If the efficiency of expression were to be compromised by the sequence of the leader peptide or its combination with FIBAC either at the protein or at the nucleic acid level, the gene could be altered to encode any of several known E. coli leader sequences.

Transcription of all of the genes discussed is effected by the lac promoter. As in the case of initiation sites for translation, the promoter and operator region of the gene may be interchanged. FIBAC may also be expressed from vectors incorporating the lambda P<sub>L</sub> promoter and operator (O<sub>L</sub>), and the hybrid promoter operator, Tac as described in Amann, E., Brosius, J., and Ptashne, M. Gene 25:167-178 (1983), specifically incorporated herein by reference. Excision of those portions of the gene including ribosome binding site structural region and 3' non-translated sequences and insertion in alternate vectors containing the P<sub>L</sub> or Tac promoter makes use of the unique restriction sites that flank these structures in pUC8-F/OmpAic and

pUC8~~S~~/OmpA1. Insertion of the Eco~~S~~ to SalI fragment from either into similarly digested plasmid pDP8 effects transcription of these genes directed by the lambda PL promoter. Transcriptional regulation would be temperature sensitive by merit of the cI857 mutation harbored on this same plasmid.

Putting similar gene fragments into the transcription unit of the Tac promoter will be accomplished by first isolating the EcoRV to SalI fragment. This, together with the synthetic Tac promoter sequence which is flanked by BamHI and PvuII sites and which contains the lac operator will be inserted into the BamHI to SalI sites of pBR322 or preferably derivatives. The derivatives in this case refer to constructs containing either the lacI gene or the I<sup>Q</sup> gene.

Expression of FIBAC in host microorganisms other than Escherichia is considered. Yeast and bacteria of the genera Bacillus, Pseudomonas, and Clostridium may each offer particular advantages. The processes outlined above could easily be adapted to others.

In general, expression vectors for any microorganism will embody features analogous to those which we have incorporated in the above mentioned vectors of E. coli. In some cases, it will be possible to simply move the specific gene constructs discussed above directly into a vector compatible with the new host. In others, it may be necessary or desirable to alter certain operational or structural elements of the gene.

EXAMPLE 3

The human collagenase inhibitor may be readily purified after expression in a variety of microbes. In each case, the spectrum of contaminant proteins will differ. Thus, appropriate purification steps will be selected from a variety of steps already known to give a good separation of the human collagenase inhibitor from other proteins and from other procedures which are likely to work.

If the inhibitor is not secreted from the microbes, it may form inclusion bodies inside the recombinant microbes. These bodies are separated from other proteins by differential centrifugation after disruption of the cells with a French Press. The insoluble inclusion bodies are solubilized in 6 M guanidine hydrochloride or 8 M urea, and the inhibitor protein is more completely solubilized by reaction of its cysteines with sodium sulfite. At any time subsequent to this step, the cysteines are converted back to their reduced form with dithiothreitol. Once the inhibitor protein is solubilized from inclusion bodies, immunoaffinity chromatography using antibodies raised against the unfolded inhibitor are used for purification before refolding.

The inhibitor can be refolded according to the protocol mentioned in Example 6, infra. After refolding of the inhibitor, or if the inhibitor is secreted from the microbes, purification from other proteins is accomplished by a variety of methods. Initial

steps include ultrafiltration through a 50 K dalton cutoff membrane or ammonium sulfate fractionation. Other useful methods include, but are not limited to, ion-exchange chromatography, gel filtration, heparin-sepharose chromatography, reversed-phase chromatography, or zinc-chelate chromatography. All of these steps have been successfully used in purification protocols. Additional high resolution steps include hydrophobic interaction chromatography or immunoaffinity chromatography. After purification, the metalloproteinase inhibitor is preferably at least 90-95% pure.

EXAMPLE 4

Purification of Human Collagenase Inhibitor from Human Amniotic Fluid

Human amniotic fluid obtained from discarded amniocentesis samples was pooled and 6 liters were subjected to ultrafiltration through a 100 kD MW cutoff filter, obtained from Millipore Corporation, in a Millipore Pellicon Cassette System. The eluate was concentrated through a 10 kD cutoff filter, obtained from Millipore Corporation, then through an Amicon PM-10 membrane. Aliquots (10 ml) of concentrated amniotic fluid were eluted through a 2.5 x 100 cm column of Ultrogel AcA54, obtained from LKB Corporation, which was equilibrated with pH 7.6, 0.05 M hepes, 1 M sodium chloride, 0.01 M calcium chloride, and 0.02% sodium azide (all chemicals were obtained from Sigma Chemical

CONFIDENTIAL

Company). Fractions containing the inhibitor were collected and pooled, dialyzed against pH 7.5, 0.025 M Hepes buffer containing 0.01 M calcium chloride and 0.02% sodium azide, and loaded onto a 1.5 x 28 cm heparin-sepharose CL-6B (obtained from Pharmacia, Inc.) column equilibrated with the same buffer. This column was rinsed with 1 liter of the above buffer and eluted with a linear gradient of 0-0.3 M sodium chloride. The fractions from the largest peak of inhibitor activity, eluting at about 0.1-0.15 M sodium chloride, were pooled, concentrated to 1 ml, and loaded onto a Synchropak rp-8 reverse phase HPLC column equilibrated with 0.05% trifluoroacetic acid (Aldrich Chemical Company). The column was eluted with a linear gradient of 0-40% acetonitrile (J. T. Baker Chemical Company) at 1/2% per minute. All fractions were immediately dried in a Savant speed-vac concentrator to remove acetonitrile, and redissolved in pH 7.5, 0.1 M Hepes before assay. The inhibitor eluted between 32-38% acetonitrile. Fractions containing the inhibitor were pooled, and 100 ul aliquots were eluted over a Bio-rad biosil-TSK 250 HPLC gel filtration column. The pooled peaks of inhibitor activity contained 0.1 mg of inhibitor, which was over 95% pure as judged by SDS-polyacrylamide gel electrophoresis.

EXAMPLE 5

Purification of Human Fibroblast Collagenase Inhibitor from Human Embryonic Skin Fibroblast Serum-Free Medium

Human embryonic skin fibroblasts were grown in serum-free tissue culture medium. Ten liters of this medium were collected, dialyzed against pH 7.5, 0.02 M hepes buffer containing 0.02% sodium azide and 0.01 M calcium chloride, and applied to a 2.8 x 48 cm column of heparin-sepharose CL-6B (Pharmacia, Inc.) equilibrated with the same buffer. The column was rinsed with 2 liters of this buffer and was then eluted with linear gradient of 0-0.3 M sodium chloride contained in this buffer. The fractions obtained were tested for the presence of inhibitor by their ability to inhibit human fibroblast collagenase. The fractions corresponding to the peak of activity were those obtained near 0.15 M sodium chloride. These fractions were concentrated to about 5 ml by ultrafiltration through an Amicon YM10 filter and the concentrate was applied in four separate runs to a 250 x 4.1 mm Synchropak rp-8 reverse phase HPLC column, equilibrated with 1% trifluoroacetic acid. The column was eluted with a 0-60% linear gradient of acetonitrile in 0.1% trifluoroacetic acid. The gradient was run at 1/2% acetonitrile per minute. The inhibitor eluted in two sharp peaks between 26-29% acetonitrile. All fractions were immediately dried in a Savant speed-vac concentrator, redissolved in pH 7.5, 0.1 M Hepes, and assayed. At least 1.2 mg of collagenase inhibitor was recovered, which was 90-95% pure.

This material gives a single band when run on a 17.5% reducing SDS gel. After carboxymethylation of the cysteines and elution through the same rp-8 column under identical conditions, the inhibitor is suitably homogenous for protein sequencing.

#### EXAMPLE 6

It is contemplated that the human collagenase inhibitor can be readily refolded into its native structure from its denatured state after expression of its gene in a microbe and separation of the collagenase inhibitor from most of the other proteins produced by the microbe. By analogy to the conditions necessary for the refolding of other disulfide-containing proteins as set forth by Freedman, R. B. and Hillson, D. A., in "Formation of Disulfide Bonds," In: The Enzymology of Post-Translational Modification of Proteins, Vol. 1, R. B. Freedman and H. C. Hawkins, eds., pp. 158-207 (1980), specifically incorporated herein by reference, refolding of the human collagenase inhibitor should occur in solutions with a pH of 8.0 or greater. At this pH, the cysteines of the protein are partially ionized, and this condition is necessary for the attainment of native disulfide bond pairings. The inhibitor concentration should be relatively low, less than 0.1 mg/ml, to minimize the formation of intermolecular disulfide-linked aggregates which will interfere with the refolding process.

Since the stability of the refolded (native) disulfide bonded structure relative to the unfolded (reduced) structure depends on both the solution oxidation-reduction potential and the concentrations of other redox-active molecules, it is contemplated that the redox potential should be buffered with a redox buffer giving a potential equivalent to a reduced: oxidized glutathione ratio of 10. The preferred concentration range of reduced glutathione would be 0.1-1.0 mM. At higher concentrations, mixed disulfides will form with protein, reducing the yield of the refolded (native) structure. The relative stabilities of the unfolded protein and the native structure, and thus the rate and yield of refolding, will also depend on other solution variables, such as the pH, temperature, type of hydrogen-ion buffer, ionic strength, and the presence or absence of particular anions or cations as discussed in Privalov, P. L., "Stability of Proteins, Small Globular Proteins," in Advances in Protein Chemistry, Vol. 33, pp. 167-236, (1979), specifically incorporated herein by reference. These conditions vary for every protein and can be determined experimentally. It is contemplated that addition of any molecule that strongly prefers to bind the native (as opposed to the unfolded) structure, and which can be readily separated afterwards from the native (refolded) protein, will increase not only the yield but the rate of re-folding. These molecules include monoclonal antibodies raised against the native structure,

and other proteins which tightly bind the native collagenase inhibitor, such as the mammalian enzymes collagenase or gelatinase

Example 7

*Sub B20*

~~The second preferred sequence as set forth herein, i.e.,~~

10	20	30	40	50	6
GGCCATCGCC	GCAGATCCAG	CGCCCAGAGA	GACACCAGAG	AACCCACCAT	GGCCCCCTT
H	F	XB	HH	N	S
A	N	HI	AH	C	A
E	U	ON	EA	O	U
3	1	21	21	1	1
70	80	90	100	110	12
GACCCCTGGC	TTCTGCATCC	TGTTGTTGCT	GTGGCTGATA	GCCCCAGCAG	GGCCTGCAC
B	SF			S	H
S	FO			A	A
T	AK			U	E
1	11			1	3
130	140	150	160	170	180
TGTGTCCCAC	CCCACCCACA	GACGGCCTTC	TGCAATTCCG	ACCTCGTCAT	CAGGGCCAA
		H	T	M	SH
		A	T	N	AA
		E	H	L	UE
		3	1	1	13
190	200	210	220	230	240
TTCGTGGGA	CACCAGAAC	CAACCAGACC	ACCTTATAACC	AGCGTTATGA	GATCAAGATC
	H			S	
	I			A	
	N			U	
	2			A	
250	260	270	280	290	300
ACCAAGATGT	ATAAAGGGTT	CCAAGCCTTA	GGGGATGCCG	CTGACATCCG	GTTCGTCTAC
	SD	FS	FN	F	H
	AD	OF	NS	O	P
	UE	KA	UP	K	A
	11	11	12	1	2
310	320	330	340	350	360
ACCCCCGCCA	TGGAGAGTGT	CTGC GGATAC	TTCCACAGGT	CCCACAACCG	CAGCGAGGAG
N			A	B	M
C			V	B	N
O			A	V	L
1			2	1	1

370	380	390	400	410	420
TTTCTCATTG	CTGGAAAAC	GCAGGATGGA	CTCTTGAC	TCACTACCTG	CAGTTTCGTC
P	F	H		P	
S	O	I		S	
T	K	N		T	
1	1	1		1	

430  
GCTCCCTGGAA AC  
B  
S  
T  
1

has the following restriction sites:

	#	SITES	FRAGMENTS	FRAGMENTS	ENDS
ACC 1 (GTVWAC)	1	295	295 (68.3) 137 (31.7)	1	295 432
AVA 2 (GGRCC)	1	338	338 (78.2) 94 (21.8)	1	338 432
BBV 1 (GCTGC)	1	350	350 (81.0) 82 (19.0)	1	350 432
BIN 1 (GGATC)	1	14	418 (96.8) 14 ( 3.2)	14	432 14
BST N1 (CCRGG)	2	65 425	360 (83.3) 65 (15.0) 7 ( 1.6)	65 1 425	425 65 432

LAW OFFICES  
FINNEGAN, HENDERSON  
FARABOW, GARRETT  
& DUNNER  
1776 K STREET, N.W.  
WASHINGTON, D.C. 20006  
(202) 293-6650

	#	SITES	FRAGMENTS	FRAGMENTS	ENDS
DDE 1 ..(CTNAG)	1	267	267 (61.8) 165 (38.2)	1 267	267 432
FNU4H 1 (GCNGC)	3	8 277 350	269 (62.3) 82 (19.0) 73 (16.9) 8 ( 1.9)	8 350 277 1	277 432 350 8
FOK 1 (GGATG)	4	76 273 285 384	197 (45.6) 99 (22.9) 76 (17.6) 48 (11.1) 12 ( 2.8)	76 285 1 384 273	273 384 76 432 285
HAE 2 (PGCGCQ)	1	19	413 (95.6) 19 ( 4.4)	19 1	432 19
HAE 3 (GGCC)	5	1 51 111 144 174	258 (59.7) 60 (13.9) 50 (11.6) 33 ( 7.6) 30 ( 6.9) 1 ( 0.2)	174 51 1 111 144 144 1	432 111 51 144 174 174 1
HHA 1 (GCGC)	1	20	412 (95.4) 20 ( 4.6)	20 1	432 20
HINC 2 (GTQPAC)	1	199	233 (53.9) 199 (46.1)	199 1	432 199

LAW OFFICES  
 FINNEGAN, HENDERSON  
 FARABOW, GARRETT  
 & DUNNER  
 1776 K STREET, N.W.  
 WASHINGTON, D.C. 20006  
 (202) 293-6850

	#	SITES	FRAGMENTS		FRAGMENTS ENDS	
HINF 1 (GANTC)	1	389	389	(90.0)	1	389
			43	(10.0)	389	432
HPA 2 (CCGG)	1	288	288	(66.7)	1	288
			144	(33.3)	288	432
MNL 1 (CCTC)	2	162	193	(44.7)	162	355
		355	162	(37.5)	1	162
			77	(17.8)	355	432
MST 2 (CCTNAGG)	1	266	266	(61.6)	1	266
			166	(38.4)	266	432
NCO 1 (CCATGG)	2	47	261	(60.4)	47	308
		308	124	(28.7)	308	432
			47	(10.9)	1	47
NSP B2 (CVGCWG)	1	278	278	(64.4)	1	278
			154	(35.6)	278	432
PST 1 (CTGCAG)	2	379	379	(87.7)	1	379
		408	29	( 6.7)	379	408
			24	( 5.6)	408	432
SAU 1 (CCTNAGG)	1	266	266	(61.6)	1	266
			166	(38.4)	266	432

LAW OFFICES  
 FINNEGAN, HENDERSON  
 FARABOW, GARRETT  
 & DUNNER  
 1775 K STREET, N.W.  
 WASHINGTON, D.C. 20006  
 (202) 293-6850

	#	SITES	FRAGMENTS	FRAGMENTS	ENDS
SAU 3A- (GATC)	2				
		14	217 (50.2)	14	231
		231	201 (46.5)	231	432
			14 ( 3.2)	1	14
SAU96 1 (GGNCC)	4				
		51	165 (38.2)	173	338
		110	94 (21.8)	338	432
		173	63 (14.6)	110	173
		338	59 (13.7)	51	110
			51 (11.8)	1	51
SCR F1 (CCNGG)	2				
		65	360 (83.3)	65	425
		425	65 (15.0)	1	65
			7 ( 1.6)	425	432
SFA N1 (GATGC)	2				
		75	199 (46.1)	75	274
		274	158 (36.6)	274	432
			75 (17.4)	1	75
STY 1 (CCRRGG)	2				
		47	261 (60.4)	47	308
		308	124 (28.7)	308	432
			47 (10.9)	1	47
TTH111 1 (GACNNNGTC)	1				
		160	272 (63.0)	160	432
			160 (37.0)	1	160
XHO 2 (PGATCQ)	1				
		13	419 (97.0)	13	432
			13 ( 3.0)	1	13

The following do not appear:

AAT 2	AFL 2	AFL 3	AHA 2
AHA 3	ALU 1	APA 1	ASU 2
AVA 1	AVA 3	AVR 2	BAL 1

LAW OFFICES  
 FINNEGAN, HENDERSON  
 FARABOW, GARRETT  
 & DUNNER  
 1775 K STREET, N.W.  
 WASHINGTON, D.C. 20006  
 (202) 293-6650

BAM H1	BAN 1	BAN 2	BCL 1
BGL 1	BGL 2	BSM 1	BSP 1286
nSSH 1	BST E2	CFR 1	CLA 1
ECO R1	ECO R5	FNUD 2	GDI 2
HAE 1	HGA 1	HGI A1	HGI C1
HGI D1	HGI J2	HIND 3	HPA 1
HPH 1	KPN 1	MBO 2	MLU 1
MST 1	NAE 1	NAR 1	NCI 1
NDE 1	NHE 1	NOT 1	NRU 1
NSP C1	PVU 1	PVU 2	RRU 1
RSA 1	SAC 1	SAC 2	SAL 1
SCA 1	SMA 1	SNA 1	SNA B1
SPE 1	SPH 1	SSP 1	STU 1
TAQ 1	XBA 1	XHO 1	XMA 3
XMN 1			

The salient features of this cDNA are:

1. The coding strand is presented in the 5' to 3' convention with the polyC tract at the 5' end.
2. If the first G in the sequence GGC CAT CGC CGC is considered as nucleotide 1, then an open reading frame exists from nucleotide 1 through nucleotide 432, which is the 3' end of this partial cDNA.
3. The first methionine in this reading frame is encoded by nucleotides 49 through 51 and represents the initiation site of translation.
4. The amino acid sequence prescribed by nucleotides 49 through 114 is not found in the primary structure of the mature protein, but it is the sequence of the leader peptide of human protein.
5. The sequence of nucleotides 82 through 432 is identical to the sequence of nucleotides numbered 1 through 351 in the insert from the first preferred sequence of Example 1.
6. The amino acid sequence of the mature protein displays two consensus sequences for sugar attachment. These sequences, -N-Q-T- prescribed by nucleotides 202 through 210 and -N-R-S- prescribed by nucleotides 346

through 354, are amino acid residues 30 through 32 and 78 through 80, respectively, in the mature protein. Both sites are glycosylated in the human inhibitor protein.

It will be apparent to those skilled in the art that various modifications and variations can be made in the processes and products of the present invention. Thus, it is intended that the present invention cover the modifications and variations of this invention provided they come within the scope of the appended claims and their equivalence.

କାହିଁ କାହିଁ କାହିଁ କାହିଁ କାହିଁ କାହିଁ କାହିଁ କାହିଁ କାହିଁ

LAW OFFICES  
FINNECAN, HENDERSON  
FARABOW, GARRETT  
& DUNNER  
1775 K STREET, N.W.  
WASHINGTON, D.C. 20006  
.202/293-6650